Tridek-One

Executive Summary

Tridek-One is a private French biotechnology company spun out from INSERM in 2018, pioneering a novel platform of first-in-class CD31 checkpoint agonist bispecific antibodies. The company's approach targets autoimmune and inflammatory diseases by selectively inhibiting pathogenic immune cell activation while preserving immune homeostasis. Leveraging the CD31 pathway, a key regulator of immune synapses, Tridek-One aims to restore immune balance without broad immunosuppression. Currently in the pre-clinical stage, the company has not disclosed funding details or specific programs, but its platform holds potential for multiple indications. The innovative mechanism and focus on immune checkpoint agonism differentiate it from conventional immune suppressants. However, the early stage and lack of publicly available data warrant cautious optimism. Key upcoming milestones include completion of IND-enabling studies and potential entry into clinical trials within the next 18-24 months, contingent on financing and regulatory clearance.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling toxicology studies60% success
• Q2 2026Series A financing round70% success
• Q2 2027First-in-human clinical trial initiation (Phase I)30% success